Additionally, the researchers also found that the receptor of interleukin-31 (IL-31), which is a favorable immune mediator in PN, was expressed in diseased fibroblasts, and therapy targeting IL-31R (Nemolizumab) could revert the changes in PN lesions. This evidence concerns the gene IL31 and poikiloderma with neutropenia.